Press Release

Events,Press Release

RepliCel Life Sciences Selected to Present at Cavendish Global Health Impact Forum

10 years ago May 06, 2015

Unique forum brings together leading family offices and foundations seeking impactful investment and philanthropic opportunities...

RepliCel Announces 2014 Fourth Quarter and Year-End Financial Results

10 years ago Apr 28, 2015

VANCOUVER, BC – April 29, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP),...

RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis

10 years ago Apr 14, 2015

The University of British Columbia Clinical Research Ethics Board Clears Clinical Trial to Proceed with...

RepliCel Life Sciences Receives TSX Venture Exchange Approval to Extend Warrant Expiry Dates

10 years ago Apr 06, 2015

VANCOUVER, BC – April 7, 2015 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)...

RepliCel Life Sciences Applies to Extend Warrant Expiry Dates

10 years ago Apr 01, 2015

VANCOUVER, BC – April 2, 2015 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)...

RepliCel Meets with Japanese Pharmaceutical and Medical Devices Agency (PMDA)

10 years ago Mar 22, 2015

As part of its Japanese partnering strategy, RepliCel seeks advice of Japanese regulators around its...

RepliCel Life Sciences in Japan for Key Industry Meetings

10 years ago Mar 11, 2015

Autologous cell therapy, RCS-01, to be investigated as a potential treatment for aged, UV-damaged skin...

RepliCel Submits Clinical Trial Application for its Dermatological Clinical Trial

10 years ago Feb 22, 2015

Autologous cell therapy, RCS-01, to be investigated as a potential treatment for aged, UV-damaged skin...

Newly Released Peer-Reviewed Publication Further Validates RepliCels Use of Dermal Sheath Cup Cells to Treat Pattern Baldness

10 years ago Dec 21, 2014

VANCOUVER, BC – December 22, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP),...

RepliCel Life Sciences Receives Health Canada Clearance for Clinical Trial in Patients with Chronic Achilles Tendinosis

10 years ago Nov 30, 2014

Health Canada Issues “No Objection Letter” for RepliCel’s Phase 1/2 Clinical Trial of RCT-01 VANCOUVER,...

RepliCel Announces 2014 Third Quarter Financial Results

10 years ago Nov 25, 2014

VANCOUVER, BC – November 26, 2014 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)...

RepliCel Submits Clinical Trial Application to Health Canada for its Chronic Achilles Tendinosis Trial

10 years ago Oct 28, 2014

Autologous cell therapy, RCT-01, to be investigated for treatment of tendinopathies refractory to other treatments...

RepliCel Life Sciences Adds Industry Specialist to Management Team

10 years ago Oct 06, 2014

Newly Appointed Vice-President of Business & Corporate Development to Drive External Initiatives VANCOUVER, BC –...

RepliCel Retains Market-Making Services

10 years ago Sep 11, 2014

VANCOUVER, BC – September 12, 2014 – RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB: REPCF)...

RepliCel Garners Feature on Fox Business News and the Financial Post

10 years ago Sep 08, 2014

RepliCel’s Innovative Technology Converts Your Own Cells into Products to Repair and Rejuvenate the Body...

RepliCel Life Sciences Joins Centre for Commercialization of Regenerative Medicine, Industry Consortium

10 years ago Sep 02, 2014

CCRM and RepliCel to Partner on Development of Cell Therapies for Tendon Repair VANCOUVER, BC...

RepliCel Announces 2014 Second Quarter Financial Results

10 years ago Aug 25, 2014

VANCOUVER, BC – August 26, 2014 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)(TSXV:RP)...

RepliCel Appoints Brooke Hurford as Corporate Secretary and Director, Finance

10 years ago Jul 15, 2014

VANCOUVER, BC – July 16, 2014 – RepliCel Life Sciences Inc. (the “Company”) (TSXV: RP)...

RepliCel Retains O&M Partners to Coordinate North American Focused Investor Marketing Campaign

10 years ago Jun 19, 2014

VANCOUVER, BC – June 20, 2014 – RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB: REPCF),...

RepliCel Life Sciences Announces Closing of Third and Final Tranche of Private Placement

10 years ago Jun 16, 2014

VANCOUVER, BC – June 17, 2014 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...

by Type

by Topic

by month

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.